13
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T1178 | Temozolomide | NSC 362856,TZM,CCRG 81045,TMZ | Apoptosis , DNA Alkylator/Crosslinker , DNA/RNA Synthesis , Autophagy |
Temozolomide (TMZ) is a DNA alkylating agent with blood-brain barrier permeability and oral activity. Temozolomide has antitumor activity and antiangiogenic activity, and also induces apoptosis and autophagy. | |||
T21463 | Temozolomide Acid | TMZA | Others |
Temozolomide Acid (TMZA) is a metabolite of temozolomide (TMZ). Temozolomide processes anticancer activity in vitro. Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocyt... | |||
T0192 | Levetiracetam | UCB L059,SIB-S1 | DNA Methyltransferase , Others , Calcium Channel |
Levetiracetam (SIB-S1) is a relatively unique anticonvulsant that is typically used in combination with other antiepileptic medications for partial onset seizures. Levetiracetam has been linked to rare instances of serum... | |||
T35688 | MTIC | NSC 407347 | Drug Metabolite |
MTIC is the active metabolite of Temozolomide (TMZ) with anticancer and antitumor activity and is used in the study of melanoma.3'-Sialyllactose (3'-SL) sodium is a prebiotic with anti-inflammatory activity. | |||
T79642 | IV-275 | Epigenetic Reader Domain | |
IV-275 is a dual inhibitor targeting the bromodomains of both BRG1 and BRM. This compound not only augments DNA damage when combined with Temozolomide and Bleomycin but also suppresses the invasiveness of GBM cells. Furt... | |||
T60870 | BRG1-IN-1 | ||
BRG1-IN-1 (Compound 11d) is a potent BRG1 inhibitor with better efficacy than PFI-3 in sensitizing GBM cells to the antiproliferative and cell death inducing effects of Temozolomide in vitro. BRG1-IN-1 enhances the inhib... | |||
T78202 | IV-255 | Epigenetic Reader Domain | |
IV-255 is a selective small molecule inhibitor of the BRG1 bromodomain, heightening DNA damage when administered with Temozolomide and Bleomycin. It also curtails the invasiveness of GBM cells and augments both Temozolom... | |||
T41151 | K34c | ||
K34c is a potent and selective α5β1 integrin inhibitor (IC50 = 3.1 nM). K34c inhibits cell survival and migration, inhibits p53-dependent senescence induced by Temozolomide or Ellipticine and promotes apoptosis in U87MG ... | |||
T61694 | PARP1-IN-10 | ||
PARP1-IN-10 (compound 12c) is a highly potent and non-cytotoxic PARP1 inhibitor, displaying an in vitro IC50 value of 50.62 nM. This compound effectively induces cell cycle arrest at the G2/M phase and apoptosis, while a... | |||
T69596 | SK-575 | ||
SK-575 is a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers. SK-575 potently inhibits the growth of cancer cells bearing BRCA1/2 mutations and induces potent and specifi... | |||
T71908 | NU1085 | ||
NU1085 is a potent poly(ADP-ribose) polymerase (PARP) inhibitors have been developed that potentiate the cytotoxicity of ionizing radiation and anticancer drugs. The biological effects of NU1085 [Ki = 6 nM], in combinati... | |||
T83912 | HR68 | PP21 | |
HR68, a derivative of the peroxisome proliferator-activated receptor (PPAR) agonist fenofibric acid, serves as an anticancer agent. It effectively reduces the viability of LN-229 glioblastoma cells, with an IC50 value of... | |||
T79487 | MAO A/HSP90-IN-2 | Monoamine Oxidase | |
MAO A/HSP90-IN-2 (compound 4-C), a dual inhibitor of HSP90 and MAO A, exhibits IC50 values of 0.016 μM for MAO A and 4.58 μM for HSP90. This compound not only enhances HSP70 expression but also diminishes HER2 and phosph... |